Company intelligence / Profile preview

Axlab

Denmark

Ownership: Private
Development stage: Other

Overview

The AS-410M robotic tissue sectioning device is FDA-cleared (2024) and clinically used in over 100 laboratories worldwide, with >85% clinical deployment. It offers high-quality sectioning, full traceability, image capture, automatic blade replacement, strong patient data safety, and consistent workflow regardless of environmental conditions. Axlab's platform delivers substantial clinical impact including reduced diagnosis turnaround time (by almost 30%) and increased work capacity (by 120%).[1][4]

Therapeutic areas: Other
Modalities: Device
Industry: Pathology

Partnerships

Dainippon Seiki (manufacturer; Axlab distributes and services AS-410M)[1]

Beyond the preview

Go deeper on Axlab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axlab.

Explore the full profile